RxDoctor Payments DataLook up a doctor →

Wissam Jaber, MD

Interventional Cardiology · Atlanta, GANPI 1053390427

Payments from drug & device makers

$981,072in general payments, 2019–2025

Across 882 payments — averaging $1112.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$456K
  • Stryker$295K
  • Medtronic$118K
  • Abbott$84K
  • EKOS Corporation$12K
  • Boston Scientific$9K
  • plus $6K from 16 others
$3,800in research payments, 2019–2025

Across 2 payments — averaging $1900.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K
  • Inari Medical, Inc.$2K

What the payments were for

  • Consulting fees$100,36345%
  • Speaking & faculty fees$71,79532%
  • Travel & lodging$36,06816%
  • Food & beverage$10,5185%
  • Education$3,0141%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$981,072 in reported general payments places this provider in the 90th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$177,268
Medicare patients
330
Services billed
1,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban167$196,678
JardianceEmpagliflozin77$98,789
FarxigaDapagliflozin Propanediol66$72,919
XareltoRivaroxaban35$45,219
Repatha SureclickEvolocumab50$37,813
EntrestoSacubitril/Valsartan31$30,320
BrilintaTicagrelor16$10,366
Repatha SyringeEvolocumab13$6,804
Ranolazine ErRanolazine33$4,617
Atorvastatin Calcium250$2,096
ClopidogrelClopidogrel Bisulfate220$2,078
Metoprolol Succinate157$1,737
Rosuvastatin Calcium135$1,440
Isosorbide Mononitrate ErIsosorbide Mononitrate50$906
Prasugrel Hcl12$852

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →